Skip to main content
19 May | 2022

A CNIC project in collaboration with the BBRC receives an Alzheimer's Disease Research Standard Award from the BrightFocus Foundation

The project focuses on the longitudinal determination of plasma biomarkers of neuronal damage, neuroinflammation and Alzheimer's disease.

17 May | 2022

The BBRC, participating center in a new clinical trial

The international study Skyline plans to enroll 1.200 participants worldwide to assess a new treatment against Alzheimer's disease.

05 May | 2022

The researcher Marta Milà defends the third doctoral thesis done at the BBRC

The thesis develved into urrent knowledge of the disease during its preclinical stage and provides new evidence for its early detection.

28 Apr | 2022

Dr. Eider Arenaza-Urquijo, named ISGlobal Associated Researcher

Currently, the BBRC researcher collaborates with ISGlobal in the NCDs (Non-Communicable Diseases) and Environment program on the effects of the pandemic on mental health.

22 Apr | 2022

Biogen, Lilly and Roche visit the new facilities of the BBRC

The pharmaceutical representatives have had a chance to see first-hand the new equipment of the Pasqual Maragall Foundation’s research center

06 Apr | 2022

The BBRC reaches 1,000 lumbar punctures in search for early detection of Alzheimer’s

Lumbar puncture is a procedure to extract cerebrospinal fluid that allows the study of biomarkers of Alzheimer's disease.

22 Mar | 2022

We share the Strategic Plan of the Pasqual Maragall Foundation 2020-2025

From our commitment to transparency, we present the strategic axes and future lines of the Pasqual Maragall Foundation to our participants in studies, partners, collaborators and civil society

21 Mar | 2022

50 researchers from around the world visit the BBRC

On the occasion of the AD / PD 2022 congress, held in Barcelona, ​​the BBRC hosted researchers from all over the world. At the meeting there was a presentation by Prof. Henrik Zetterberg of the University of Gothenburg

14 Mar | 2022

The BBRC, selected as participating center in a new global study on Alzheimer's

This is the AHEAD clinical trial, an international multicenter study to evaluate the efficacy and safety of lecanemab